Chronic Pain Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceAnti-inflammatory effects reduce pain signaling; may reduce NSAID requirements
Deficiency linked to chronic pain; supplementation may reduce pain especially in deficient patients
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsAnti-inflammatory comparable to NSAIDs in some studies; reduces pain in osteoarthritis and other conditions
Supporting Studies (1)
NMDA receptor antagonist; reduces pain sensitization; helps with muscle tension and migraines
Supporting Studies (1)
Endocannabinoid-like compound; reduces inflammation and pain signaling; studied for neuropathic and chronic pain
Supporting Studies (1)
5-LOX inhibitor with anti-inflammatory effects; studied for osteoarthritis and inflammatory pain
Supporting Studies (1)
Antioxidant with specific efficacy for neuropathic pain conditions
Supporting Studies (1)
B1, B6, B12 support nerve health; may help with neuropathic pain components
Supporting Studies (1)
May help with fibromyalgia and osteoarthritis pain; supports mood which affects pain perception
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Chronic pain is pain lasting more than 3-6 months, persisting beyond normal tissue healing time. It affects about 20% of adults and can significantly impact quality of life, sleep, mood, and function. Chronic pain involves complex changes in the nervous system that make the pain system hypersensitive.
CRITICAL: Chronic pain requires a comprehensive, multimodal approach. Supplements are ONE component of a broader treatment plan.
COMPREHENSIVE PAIN MANAGEMENT includes:
WHEN TO SEE A DOCTOR:
* Omega-3 Fatty Acids reduce inflammation throughout the body and may decrease the need for NSAIDs.
* Vitamin D deficiency is extremely common in chronic pain patients. Correction of deficiency often improves pain.
* Curcumin has anti-inflammatory effects comparable to NSAIDs in some studies, particularly for joint pain.
* Magnesium blocks NMDA receptors involved in pain amplification and may reduce central sensitization.
* PEA (Palmitoylethanolamide) is a naturally occurring compound that reduces inflammation and pain signaling.
Expected timeline: Anti-inflammatory supplements typically require 4-8 weeks to show benefit. A multimodal approach provides the best outcomes for chronic pain.
Clinical Perspective
Chronic Pain: Pain persisting >3-6 months beyond expected healing. Types: nociceptive (tissue-based), neuropathic (nerve damage), nociplastic (central sensitization). Common conditions: low back pain, osteoarthritis, neuropathy, fibromyalgia, headaches. Biopsychosocial model: pain influenced by biological, psychological, and social factors - all must be addressed. Central sensitization: nervous system changes amplifying pain; requires multimodal treatment.
CRITICAL: Chronic pain requires multimodal, interdisciplinary approach. Elements: physical therapy, psychological therapies (CBT, ACT), pharmacotherapy (NSAIDs, antidepressants, anticonvulsants, topicals), interventional if appropriate, self-management strategies. Avoid opioid monotherapy for chronic non-cancer pain - limited efficacy, significant risks. Supplements are ADJUNCTIVE.
* Omega-3 Fatty Acids (B-grade): Anti-inflammatory. Systematic review: (PMID: 27840029). Meta-analysis: (PMID: 25340061). 2-4g EPA+DHA daily.
* Vitamin D (B-grade): Common deficiency; pain association. Systematic review: (PMID: 28750270). 2000-4000 IU daily; correct deficiency.
* Curcumin (B-grade): COX/LOX inhibition. Meta-analysis: (PMID: 25282711). 500-1500mg daily. Enhanced absorption forms.
* Magnesium (B-grade): NMDA antagonist; sensitization. Systematic review: (PMID: 28445426). 300-500mg daily.
* PEA (B-grade): Endocannabinoid pathway. Meta-analysis: (PMID: 29430697). 600-1200mg daily. Good safety profile.
* Boswellia (B-grade): 5-LOX inhibition. Systematic review: (PMID: 26218979). 300-500mg AKBA TID.
* Alpha-Lipoic Acid (B-grade): Neuropathic pain. Meta-analysis: (PMID: 27840029). 600mg daily.
* B-Complex (C-grade): Nerve support. Review: (PMID: 28660890). Daily; avoid >100mg B6.
* SAMe (B-grade): OA, fibromyalgia. Meta-analysis: OA (PMID: 12614626). 800-1600mg daily.
Assessment targets: Pain intensity (NRS), pain interference (BPI), function, mood, sleep, quality of life, NSAID/opioid use.
Protocol notes: Movement is medicine: exercise shown to reduce chronic pain despite initial discomfort; graded activity approach. Sleep: poor sleep amplifies pain; address sleep hygiene, consider CBT-I. Psychological: catastrophizing, fear-avoidance, depression worsen outcomes - CBT effective. Central sensitization: features include widespread pain, sensitivity to touch, noise, temperature - PEA, magnesium, duloxetine may help. Opioids: limited evidence for long-term chronic non-cancer pain; hyperalgesia, tolerance, dependence risks; taper if on long-term. Topicals: capsaicin, lidocaine for localized pain - fewer systemic effects. Inflammation: chronic low-grade inflammation (hs-CRP) may predict response to anti-inflammatory approaches. Gut health: pain-gut connection emerging; consider probiotics if GI symptoms. Combination supplements: often more effective than single agents - curcumin + boswellia + omega-3. Timeline: set realistic expectations - improvement gradual; 25-50% pain reduction often meaningful.